IVD Trends and Market Update, March 2022

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,000	58 Pages	Kalorama Information	March, 2022	KLI17071365

Attention: There is an updated edition available for this report.

Best Price Guarantee
Price	from $5,000
Length	58 Pages
Publisher	Kalorama Information
Published Date	March, 2022
SKU	KLI17071365

IVD Trends and Market Update, March 2022

What’s Driving Growth in the IVD Market in 2022?

What Major Trends are Affecting the Market in 2022?

How Has COVID-19 Impacted and Continued to Impact the Market in 2022?

What Product Trends and New Developments Will Shape the IVD Market in 2022?

Diagnostic test products have never been more important. This report is an update of the market for in vitro diagnostics products from Kalorama’s analysts to reflect the latest information as of Q1 2022.

The demand for testing and movement of current and new technologies has continued to demonstrate gains in most areas of the IVD market. New products, changes in global health spending, regulatory changes in major markets and disease trends are among the factors that produce a constantly evolving market picture. There are some growing segments in the market that have attracted industry attention. Among these are next-generation sequencing (NGS), personalized medicine and mass spectrometry. Immunochemistry, point-of-care (POC) testing, and molecular diagnostics are also segments of great market interest, anticipated to be a core part of the future of IVD. The IVD market remains dynamic, demonstrating constant innovations.

Kalorama Information continues to be diligent in outlining the IVD market and its rapidly changing landscape. Kalorama Information has been and continues to be superior in accessing the market due to the extensive experience of its authors and commitment by the company to present the most accurate data available.

Worldwide IVD Market – March 2022 Update
- IVD Market Demand and Growth
  - Table Quarter-by-Quarter Segment Performance Commentary, 2021
  - Table Global In Vitro Diagnostic Sales by Product Market, 2021 ($ million) (Clinical Chemistry; Immunoassays - non isotopic: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab; Hematology - Core Lab; Microbiology (ID/AST); Microbiology (molecular); Microbiology - Mass Spectrometry; Coagulation (PT/INR); Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)
  - Table IVD Segment Performance, Q1 2021 – Q4 2021 ($MN)
  - Table IVD Segment Performance, Total Market Value, 2021 ($MN)
  - COVID-19 Diagnostic Markets
- Effect of COVID-19 on Market Segments
  - Table IVD Market excluding and with COVID-19, 2021
  - Table IVD Market Distribution by Segment
  - Table Global In Vitro Diagnostic Market – YoY Growth 2020-2021
  - Table Global In Vitro Diagnostic Market – YoY Growth 2020-2021
Product Trends and New Developments
- Selected New - Q4 2021 and Q1 2022 - Core IVD Product Launches, Developments and Trends
  - Clinical Chemistry
  - Flow Cytometry
  - Immunoassay
  - Mass Spectrometry
  - Molecular
  - Personalized Medicine
  - POC
  - Sequencing
- COVID-19 Developments – Q1 2021 Through Q4 2021
  - Table COVID-19 Test Market by Type, Q1-Q4 2021 Estimates – Rapid Testing Markets Remain Strong
  - Antigen
  - Molecular
Top IVD Market Participant Results
- Selected Competitive Leader Updates
  - Table IVD Segment Growth by Leading Competitors, Change in Sales 2020-2021
  - Table Changes in Market Distribution for IVD Sales, 2019 & 2021 – Roche and Abbott Tie for #1 Spot
- 2021 M&A Activity
  - Table IVD-Relevant M&A Activity, 2021
  - Table Count of IVD Industry M&A Deals by Month, 2021
- Abbott Laboratories
  - Table Abbott Corporate Summary
  - Table Abbott Diagnostics Revenue by Segment (Core Laboratory, Molecular, Point-of-Care, Rapid Diagnostics, COVID-19, BinaxNOW/ID NOW) Full Year 2020 and 2021
- Becton Dickinson and Co
  - Table Becton Dickinson Corporate Summary
  - Table BD Life Sciences, Revenues by Business FY End September 30, 2020, and 2021
- bioMérieux SA
  - Table bioMérieux Corporate Summary
  - Table bioMérieux Clinical Applications Segment, Full Year Results, 2020,2021
- Danaher Corporation
  - Table Danaher Corporation Summary
  - Table Danaher Diagnostic Segment Performance, Full Year Results, 2020,2021
- Hologic, Inc.
  - Table Hologic Corporate Summary
  - Table Hologic Diagnostic Segment Performance, Full Year Results, FY 2020, FY 2021, $M
- Ortho Clinical Diagnostics
  - Table Ortho Clinical Corporate Summary
  - Table Ortho Clinical Diagnostics, Full Year Results, $M (2020, 2021)
- PerkinElmer, Inc.
  - Table Perkin Elmer Corporate Summary
  - Table PerkinElmer Diagnostics (Product, Service Revenue), Full Year Results, $M (2020, 2021)
- Quidel Corporation
  - Table Quidel Corporate Summary
  - Table Quidel Corporation Revenue by Product Group, Full Year Results 2020, 2021, $M
- Roche Diagnostic
  - Table Roche Diagnostic Corporate Summary
  - Table Roche Diagnostics Revenue by Product Group, Full Year Results 2020, 2021, CHF MN
- Siemens Healthineers
  - Table Siemens Healthineers Corporate Summary
  - Table Siemens Diagnostics Revenue, FY 2020 and FY 2021, €MN
- Sysmex Corporation
  - Table Sysmex Corporate Summary
  - Table Sysmex Revenue by Product Segment, FY 2020, 2021 and 2022, JPY MN
- Thermo Fisher Scientific
  - Table Thermo Fisher Scientific Corporate Summary
  - Table Thermo Fisher Scientific COVID-19 Response Revenue, 2020 and 2021 by Quarter
New Opportunities
- Artificial Intelligence in the Lab
- Multiplex and Syndromic Testing
- Advancing Lateral Flow Technologies
- Personalized Medicine
- Point-of-Care
- Mass Spectrometry-based COVID-19 Testing